

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT

- (1) PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS;**
- (2) PROPOSED RE-ELECTION AND APPOINTMENT OF SUPERVISORS;**
- (3) CHANGE OF COMPOSITION OF BOARD COMMITTEE ; AND**
- (4) CLOSURE OF THE REGISTER OF MEMBERS**

PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS

The Board hereby announces that as the term of office of the fifth session of the Board will expire on 17 September 2023, it resolved at the meeting of the Board held on 25 August 2023 to propose to re-elect Mr. Yu Qingming and Mr. Liu Yong as executive Directors of the sixth session of the Board; to re-elect Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli as non-executive Directors of the sixth session of the Board; and to re-elect Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao as independent non-executive Directors of the sixth session of the Board. Meanwhile, in view of the retirement of Mr. Ma Ping, a non-executive Director, the Board resolved at the same meeting to propose to appoint Mr. Wang Peng as a non-executive Director of the sixth session of the Board.

PROPOSED RE-ELECTION AND APPOINTMENT OF SUPERVISORS

The Board further announces that as the term of office of the fifth session of the Supervisory Committee will also expire on 17 September 2023, the Supervisory Committee resolved at the meeting of the Supervisory Committee held on 25 August 2023 to propose to re-elect Ms. Guan Xiaohui and Mr. Liu Zhengdong as independent Supervisors of the sixth session of the Supervisory Committee. Meanwhile, in view of the retirement of Mr. Wang Peng, a shareholder

* *The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*

representative Supervisor, the Supervisory Committee resolved at such meeting to propose to appoint Mr. Guo Jinhong as the shareholder representative Supervisor of the sixth session of the Supervisory Committee.

In accordance with the Articles of Association, the above proposed re-election and appointment of Directors and proposed re-election and appointment of Supervisors are subject to the approval by the Shareholders at the general meeting of the Company, while the employee representative Supervisors of the sixth session of the Supervisory Committee shall be elected democratically by the employees of the Company and is not subject to the Shareholders' approval. The Company proposed to convene and hold an extraordinary general meeting on Friday, 15 September 2023 to seek the approval of the Shareholders with respect to the proposed re-election and appointment of Directors and proposed re-election and appointment of Supervisors.

CHANGE OF COMPOSITION OF BOARD COMMITTEE

The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect.

(1) PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS

Proposed Re-election of Directors

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Group Co. Ltd. (the “**Company**”, together with its subsidiaries, collectively as the “**Group**”) hereby announces that as the term of office of the fifth session of the Board will expire on 17 September 2023, it resolved at the meeting of the Board held on 25 August 2023 to propose to re-elect Mr. Yu Qingming and Mr. Liu Yong as executive Directors of the sixth session of the Board; to re-elect Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli as non-executive Directors of the sixth session of the Board; and to re-elect Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao as independent non-executive Directors of the sixth session of the Board.

Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao have all confirmed their compliance with the independence guidelines as set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”). The nomination committee of the Board (the “**Nomination Committee**”) had assessed, based on the independence criteria as set out in Rule 3.13 of the Hong Kong Listing Rules, and reviewed the written confirmation of independence of each of Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao and is satisfied that each of Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao is independent.

In addition, when considering the candidates of independent non-executive Directors for the sixth session of the Board, the Nomination Committee and the Board has considered the independence confirmations of Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao and their skills, background, knowledge and experience. In particular, Mr. Chen Fangruo has extensive experience in strategic management, Mr. Li Peiyu has extensive experience in corporate management and macroeconomic research, Mr. Wu Tak Lung has extensive experience in finance, Mr. Yu Weifeng has extensive experience in law and Mr. Shi Shenghao has extensive experience in medical health industry, industry operation and investment. Their different education, background, professional experience and practice enable them to provide relevant valuable insights and contribute to the diversity of the Board.

Retirement of Non-executive Director

Mr. Ma Ping, a non-executive Director of the fifth session of the Board, will retire upon the approval of appointment of Directors of the sixth session of the Board at the extraordinary general meeting of the Company. Mr. Ma Ping has confirmed that he has no disagreement with the Board, and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders (the “**Shareholders**”) and creditors of the Company. The Board would like to take this opportunity to express its sincere gratitude to Mr. Ma Ping for his contributions to the Company during his tenure as a Director.

Proposed Appointment of Directors

The Board resolved at the meeting of the Board held on 25 August 2023 to propose to appoint Mr. Wang Peng as a non-executive Director of the sixth session of the Board at such meeting.

The above proposed appointment was proposed by the Nomination Committee according to the nomination procedure for Directors of the Company and based on the needs of the Company and submitted to the Board for review after considering the Director candidate’s relevant qualification by the Nomination Committee, and will then be submitted by the Board to the extraordinary general meeting for final approval.

In accordance with the articles of association of the Company (the “**Articles of Association**”), the above proposed re-election and appointment of Directors is subject to the approval by the Shareholders at the general meeting of the Company.

Upon the above proposed re-election and appointment of Directors of the sixth session of the Board being approved by the Shareholders, the Company will enter into service contract with each of them. The term of office of each of them as a Director of the sixth session of the Board will be three years from the date of approval by the Shareholders. Pursuant to the Articles of Association, each of the above proposed re-elected and appointed Directors will be subject to retirement by rotation and re-election upon the expiry of his/her term of office. The remuneration of each of them for serving as an executive Director, non-executive Director or independent non-executive Director of the sixth session of the Board will be determined by the

Board according to the authorisation granted by the Shareholders at the annual general meeting of the Company held on 15 June 2023 and in accordance with the Company's remuneration standard regarding Directors. At present, according to the Company's 2023 remuneration standard, the remuneration of independent non-executive Directors will be RMB350,000 per annum (before tax); non-executive Directors will not receive any remuneration from the Company; executive Directors will receive remuneration based on the performance appraisal, incentive measures and annual salary standard settlement.

Biographies of the Director candidates for the sixth session of the Board are set out in Appendix I to this announcement.

(2) PROPOSED RE-ELECTION AND APPOINTMENT OF SUPERVISORS

Proposed Re-election of Supervisors

The Board further announces that as the term of office of the fifth session of the supervisory committee (the “**Supervisory Committee**”) will also expire on 17 September 2023, the Supervisory Committee resolved at the meeting of the Supervisory Committee held on 25 August 2023 to propose to re-elect Ms. Guan Xiaohui and Mr. Liu Zhengdong as independent Supervisors (the “**Supervisor**”) of the sixth session of the Supervisory Committee.

Retirement of Shareholder Representative Supervisor

Mr. Wang Peng, a shareholder representative Supervisor of the fifth session of the Supervisory Committee, will retire upon the approval of appointment of Supervisors of the sixth session of the Supervisory Committee at the extraordinary general meeting of the Company. Mr. Wang Peng has confirmed that he has no disagreement with the Supervisory Committee, and there is no other matters relating to his resignation as a Supervisor that needs to be brought to the attention of the Shareholders and creditors of the Company. The Supervisory Committee would like to take this opportunity to express its sincere gratitude to Mr. Wang Peng for his contributions to the Company during his tenure as a Supervisor.

Proposed Appointment of Supervisor

The Supervisory Committee resolved at the meeting of the Supervisory Committee held on 25 August 2023 to propose to appoint Mr. Guo Jinhong as a shareholder representative Supervisor of the sixth session of the Supervisory Committee.

In accordance with the Articles of Association, the above proposed re-election and appointment of Supervisors are subject to the approval by the Shareholders at the general meeting of the Company, while the employee representative Supervisors of the sixth session of the Supervisory Committee shall be elected democratically by the employees of the Company and is not subject to the Shareholders' approval.

Upon the above proposed re-election and appointment of independent Supervisors and shareholder representative Supervisor of the sixth session of the Supervisory Committee being approved by the Shareholders, the Company will enter into service contract with each of them. The term of office of each of them as a Supervisor of the sixth session of the Supervisory Committee will be three years from the date of approval by the Shareholders. Pursuant to the Articles of Association, each of the above proposed re-elected and appointed Supervisors will be subject to retirement by rotation and re-election upon the expiry of his/her term of office. The remuneration of each of them for serving as a shareholder representative Supervisor and an independent Supervisor of the sixth session of the Supervisory Committee will be determined by the Supervisory Committee according to the authorisation granted by the Shareholders at the annual general meeting of the Company held on 15 June 2023 and with reference to their duties in the Company, the Company's business performance and the prevailing market condition. At present, according to the Company's 2023 remuneration standard, the remuneration of Mr. Liu Zhengdong, an independent Supervisor, will be RMB350,000 per annum (before tax) and other Supervisors (excluding employee representative Supervisors) will not receive any remuneration from the Company.

Biographies of the shareholder representative Supervisor and independent Supervisor candidates for the sixth session of the Supervisory Committee are set out in Appendix II to this announcement.

(3) CHANGE OF COMPOSITION OF BOARD COMMITTEE

The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect.

(4) CLOSURE OF THE REGISTER OF MEMBERS

The Company proposed to convene and hold an extraordinary general meeting on Friday, 15 September 2023 to seek the approval of the Shareholders with respect to the proposed re-election and appointment of Directors and proposed re-election and appointment of Supervisors.

In accordance with the Articles of Association, for the purpose of holding the extraordinary general meeting, the register of members of the Company (the "**Register**") will be closed from Tuesday, 12 September 2023 to Friday, 15 September 2023 (both days inclusive) during which period no transfer of shares of the Company will be registered.

In order to be qualified to attend and vote at the extraordinary general meeting, for holders of H shares of the Company, all transfer documents accompanied by the relevant share certificates must be lodged with the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as practicable, and in any event no later than 4:30 p.m. on Monday, 11 September 2023.

The Shareholders whose names appear on the Register on Tuesday, 12 September 2023 are entitled to attend and vote at the extraordinary general meeting.

A circular containing, among other things, further details of the proposed re-election and appointment of Directors and proposed re-election and appointment of Supervisors and a notice of the extraordinary general meeting will be despatched to the Shareholders in due course.

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
25 August 2023

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.

APPENDIX I BIOGRAPHIES OF THE DIRECTOR CANDIDATES FOR THE SIXTH SESSION OF THE BOARD

EXECUTIVE DIRECTORS

Mr. Yu Qingming, aged 59, is the chairman, executive Director and the secretary of Party Committee of the Company. Mr. Yu has over 36 years of working experience in the pharmaceuticals industry, especially in the management of pharmaceuticals and medical devices, and holds the professional title of senior engineer. Mr. Yu graduated from the Party School of the Central Committee of C.P.C majoring in economic management with a master degree. From July 1987 to February 1997, Mr. Yu successively worked at Beijing Pharmaceutical Station of CNPGC, China Medical Instrument Corporation and State Pharmaceutical Administration; from February 1997 to August 2010, Mr. Yu successively held senior management positions in The United Laboratories International Holdings Limited and China Medical Instrument Corporation. Mr. Yu has taken senior management positions of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. since August 2010. He currently serves as a director of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. Mr. Yu joined the Group since December 2018 and currently serves as secretary of Party Committee, chairman and executive Director of the Company. Mr. Yu currently serves as director and general manager of Sinopharm Industrial Investment Co., Ltd. (“**Sinopharm Investment**”). Mr. Yu is currently also a representative of the 14th National People’s Congress, a party representative of the 12th Party Congress of Shanghai, vice president of China Association for Medical Devices Industry, vice chairman of China Association of Medical Equipment, and chairman of Medical Device Manager 50 Forum (MD50) etc. He is appointed as part-time professor in various universities such as East China University of Science and Technology and Shanghai University of Medicine & Health Sciences.

Mr. Liu Yong, aged 54, is an executive Director, president and deputy secretary of Party Committee of the Company. Mr. Liu has over 31 years of working experience, over 28 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a doctoral degree in social and administrative pharmacy from China Pharmaceutical University. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu joined the Group since July 1992. He worked at Shanghai Pharmaceutical Station, China National Pharmaceutical Group Shanghai Co., Ltd., Shanghai Guoda Drug Chain Store Co., Ltd. and Sinopharm Holding Shenyang Co., Ltd. Mr. Liu held senior management positions in the Company since January 2009, and is currently also an executive Director, president and deputy secretary of Party Committee of the Company. Mr. Liu is currently a representative of the 16th People’s Congress of Shanghai, and also serves as the vice chairman of Shanghai Shyndec Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600420) (“**Shyndec Pharmaceutical**”), and served as a director of Sinopharm Investment, China National Medicines Corporation Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600511)(“**Sinopharm (CNMC LTD)**”), and China National Accord Medicines Corporation Ltd. (a company listed on the Shenzhen Stock Exchange, A share stock code: 000028 and B share stock code: 200028) (“**Sinopharm Accord**”) and takes senior management positions in a number of subsidiaries.

NON-EXECUTIVE DIRECTORS

Mr. Chen Qiyu, aged 51, is a non-executive Director and vice chairman of the Company. Mr. Chen has nearly 30 years of working experience. He obtained a bachelor's degree in genetics from Fudan University in July 1993 and an executive master's degree in business administration from China Europe International Business School in September 2005. Mr. Chen has joined Fosun Pharma Group (namely Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**") and its holding subsidiaries/units, hereafter the same) since 1994, and is currently the executive director and joint chief executive officer of Fosun International Limited (a company listed on the Hong Kong Stock Exchange (stock code: 00656)) ("**Fosun International**"), the non-executive director of Fosun Pharma (a company listed on the Shanghai Stock Exchange (stock code: 600196) and the Hong Kong Stock Exchange (stock code: 02196)), non-executive director of Shanghai Henlius Biotech, Inc. (a company listed on the Hong Kong Stock Exchange (stock code: 02696)) ("**Henlius**"), and non-executive director of Gland Pharma Limited (a company listed on Bombay Stock Exchange and National Stock Exchange of India, stock code: GLAND and GLAND) ("**GLAND**"). Mr. Chen has joined the Company since January 2003, and served as the chief Supervisor and non-executive Director of the Company, and is currently the non-executive Director and vice chairman of the Company. Mr. Chen served as the co-chairman of New Frontier Health Corporation (a company delisted from the NYSE in January 2022) and a director of Beijing Sanyuan Food Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600429). Mr. Chen concurrently served as the deputy chairman of Sinopharm Investment. Mr. Chen is currently the chairman of China Medical Pharmaceutical Material Association, vice chairman of China Pharmaceutical Innovation and Research Development Association, honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, the standing member of the 14th Shanghai Committee of the Chinese People's Political Consultative Conference and part-time vice chairman of Shanghai Federation of Industry and Commerce (General Chamber of Commerce).

Mr. Hu Jianwei, aged 49, is a non-executive Director of the Company. Mr. Hu worked at government agencies for a long time from July 1994 to November 2017. He has in-depth research on macroeconomic operation and management and is familiar with medical and health work. He has served as a member of Party Committee and deputy general manager of China National Pharmaceutical Group Co., Ltd. ("**CNPGC**") since December 2017, and general counsel since January 2019, mainly responsible for work such as strategic planning, branding, operation and legal affairs. Mr. Hu has served as a non-executive Director since he joined the Group in December 2018.

Mr. Deng Jindong, aged 59, is a non-executive Director of the Company. He has over 35 years of working experience, over 30 years of which is financial management experience. Mr. Deng obtained a master's degree in economics from Central Institute of Finance and Economics (currently known as Central University of Finance & Economics) in January 1991. He is a non-practising PRC certified public accountant. Mr. Deng previously worked at Economic Information Network Data Co., Ltd. and Taikang Life Insurance Co., Ltd. Mr. Deng joined CNPGC since October 2002, and successively served as the head of the finance department and the chief accountant, and has served as the vice general manager of CNPGC since May 2017. Mr. Deng is currently also the chairman of Sinopharm Investment.

Mr. Wang Kan, aged 38, is a non-executive Director of the Company. Mr. Wang obtained a master's degree of science in pharmacognosy from the School of Pharmaceutical Sciences of Peking University Health Science Center in July 2009. Mr. Wang successively worked at the planning development and industrial management department of China National Pharmaceutical Industry Corporation Ltd. and the investment management department and securities department of China National Biotec Group Co., Ltd. respectively from August 2009 to November 2014. Mr. Wang has worked for CNPGC since November 2014 and held positions of the officer assistant and the deputy officer of the investment management department. He has been serving as the officer of the investment management department and the deputy officer of policy study office of CNPGC since August 2021. Mr. Wang has been a non-executive Director of the Company since December 2022. At present, Mr. Wang also serves as the director of China National Biotec Group Co., Ltd., China Traditional Chinese Medicine Holdings Co. Limited (a company listed on the Hong Kong Stock Exchange, stock code: 00570), China National Corp. of Traditional and Herbal Medicine, Chongqing Taiji Industry (Group) Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600129) and Fresenius Kabi Huarui Pharmaceutical Co., Ltd.

Mr. Wang Peng, aged 40, is a certified public accountant, an international certified internal auditor and a certified management accountant in the United States. Mr. Wang obtained a master's degree of economics in international trade from Tianjin University of Finance and Economics in June 2008 and obtained a master's degree of business administration from Guanghua School of Management in Peking University in June 2022. Mr. Wang worked at Tianjin Branch of Deloitte Touche Tohmatsu Certified Public Accountants LLP, Tianjin Branch of Standard Chartered Bank (China) Limited and Vcanland Holdings Group Company Limited (永泰紅礮控股集團有限公司) respectively from July 2008 to October 2015. Mr. Wang successively served as the financial manager of Vcanbio Cell & Gene Engineering Co., Ltd. since October 2015 and the financial director of the company from August 2017 to April 2022. Mr. Wang has been serving as the officer of the finance department of CNPGC since May 2022. Mr. Wang has been serving as a Supervisor of the Company since December 2022. Mr. Wang has served as a director of Shanghai Shyndec Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600420) since November 2022 and a director of Sinopharm Group Finance Co., Ltd. (國藥集團財務有限公司) since April 2023.

Mr. Wen Deyong, aged 52, is a non-executive Director of the Company. Mr. Wen graduated from Donghua University and received a master's degree in business administration in December 2007. Mr. Wen joined Fosun Pharma Group in May 2002, and is currently the executive director and the chief executive officer (CEO) of Fosun Pharma, and non-executive director of Henlius. Mr. Wen worked at Chongqing Yaoyou Pharmaceutical Co., Ltd. and Chongqing Healthman Pharma Co., Ltd. from September 1995 to May 2016. Mr. Wen has served as the non-executive Director of the Company since September 2017. Mr. Wen is currently also the director of Sinopharm Investment and Sinopharm (CNMC LTD), and a supervisor of Sinopharm Accord. Mr. Wen was also the director of Anhui Sunhere Pharmaceutical Excipients Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 300452) and C.Q. Pharmaceutical Holding Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 000950).

Mr. Li Dongjiu, aged 58, is a non-executive Director of the Company. Mr. Li has over 35 years of working experience in the pharmaceutical industry, over 30 years of which relates to management experience in the pharmaceutical and healthcare products industry. Mr. Li is a professor-level senior engineer. Mr. Li obtained a PhD degree of transportation planning and management from Wuhan University of Technology, and then obtained an EMBA degree from China Europe International Business School. Mr. Li held senior management positions in North China Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600812) from July 1987 to December 2009. Mr. Li joined Fosun Pharma Group for the first time in December 2009 and successively served as the president of Shanghai Fosun Pharmaceutical Development Co., Ltd., the chairman of the Commercialisation and Consumer Products Management Committee of Fosun Pharmaceutical, the senior vice president of Fosun Pharmaceutical, and also served as the director of Nature's Sunshine Products Inc (a company listed on the NASDAQ, NASDAQ: NATR) from December 2009 to January 2018; and rejoined Fosun Pharma Group in March 2021 and is currently serving as the senior vice president of Fosun Pharma. Mr. Li served as a non-executive Director of the Company from October 2013 to January 2018 and served as a vice president and chief legal advisor of the Company from January 2018 to March 2021. Mr. Li once served as a director of Sinopharm (CNMC LTD) and Sinopharm Accord. Mr. Li has been a non-executive Director of the Company since June 2021.

Ms. Feng Rongli, aged 48, is a non-executive Director of the Company. Ms. Feng graduated from Shanghai University with a major in microcomputer application in July 1996 and obtained a master's degree in business administration from Columbia Southern University in February 2002. Ms. Feng has extensive experience in the field of human resources management. Ms. Feng held human resources management positions in Sealed Air Packaging (Shanghai) Co., Ltd. (希悅爾包裝(上海)有限公司), Grundfos Pumps (Shanghai) Co., Ltd. (格蘭富水泵(上海)有限公司), Emerson Electric (China) Holdings Co., Ltd. (艾默生電氣(中國)投資有限公司), Dow Chemical (China) Co., Ltd. (陶氏化學(中國)有限公司), Shanghai Roche Pharmaceutical Co., Ltd. (上海羅氏製藥有限公司), and F. Hoffmann-La Roche AG from July 1996 to February 2015. Ms. Feng served as the deputy chief human resources officer of Shanghai Fosun High Technology (Group) Company Limited and the managing director of the human resources of Shanghai Fosun Venture Capital Investment Management Co., Ltd. (上海復星創業投資管理有限公司) from July 2018 to April 2020. Ms. Feng joined Fosun Pharma Group since April 2020 and is currently serving as the senior vice president of Fosun Pharma. Ms. Feng currently serves as the chairman of the supervisory committee of Henlius and the non-executive director of Sisram Medical Ltd (a company listed on the Hong Kong Stock Exchange, stock code: 01696). Ms. Feng has served as the non-executive Director of the Company since June 2020.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Chen Fangruo, aged 58, is an independent non-executive Director of the Company. Mr. Chen obtained a Master's Degree from the Moore School of Electrical Engineering, University of Pennsylvania in 1987. He then received his Ph.D. degree from the Wharton School at the University of Pennsylvania. Mr. Chen worked at Columbia Business School in 1992, successively serving as the Assistant Professor, Associate Professor, Lifetime Associate Professor and Full Professor. In 2005, he became the Lifetime Chair Professor. During the foregoing period, Mr. Chen acted as a distinguished

visiting professor at Stanford School of Business, Cheung Kong Graduate School of Business, Chinese Academy of Sciences, Shanghai Jiao Tong University, Peking University, Tianjin University and other prestigious universities at home and abroad. Mr. Chen has served as the independent non-executive Director of the Company since December 2018. Mr. Chen is currently a “Guangqi” fund sponsored professor, the Dean of Antai College of Economics and Management, the Dean of the Industry Research Institute, the Dean of the BOC Institute of Technology & Finance and the Dean of the Shenzhen Research Institute of Shanghai Jiao Tong University. Since 2019, he has served concurrently as the vice chairman of the National MBA Education Instruction Committee and a director of the AMBA & BGA’s International Management Board. Currently, Mr. Chen also served as the independent director of Yunnan Jianzhijia Health-Chain Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 605266).

Mr. Li Peiyu, aged 60, is an independent non-executive Director of the Company. Mr. Li obtained a PhD of management in Management Science and Engineering from School of Economics and Management, Tsinghua University and a Master of Public Administration (MPA) from Harvard University in June 1998. Mr. Li has worked in the areas of economics, finance and management for more than 30 years. From July 1987 to September 2000, he held positions in the Development Research Center of the State Council. From September 2000 to December 2007, Mr. Li successively served as the deputy director of Henan Provincial Development Planning Committee and the mayor of Hebi City in Henan Province. From December 2007 to November 2020, Mr. Li successively served as director of alternative investment department of China Investment Corporation, inspector of the research office of the State Council, chairman of China Reinsurance (Group) Corporation, and managing director of Beijing Zhongyu Green Investment Management Co., Ltd., managing director of CASIC Investment Fund Management (Beijing) Limited Company (航天科工投資基金管理(北京)有限公司) and the partner of the Beijing Qiyuanhouji Investment Management Co., Ltd. (北京啟源厚積投資管理有限公司). Mr. Li served as the managing director of Lotus Lake Venture Capital Management (Beijing) Co., Ltd. (荷塘創業投資管理(北京)有限公司) from January 2022 to February 2023. Mr. Li has served as the independent non-executive Director of the Company since September 2020.

Mr. Wu Tak Lung, aged 58, is an independent non-executive Director of the Company. Mr. Wu received a bachelor’s degree in Business Administration from the Hong Kong Baptist University and a master’s degree in business administration jointly from the University of Manchester and the University of Wales, respectively. Mr. Wu currently serves as an independent non-executive director of Kam Hing International Holdings Limited (a company listed on the Hong Kong Stock Exchange, stock code: 2307), Henan Jinma Energy Company Limited (a company listed on the Hong Kong Stock Exchange, stock code: 6885) and Zhongguancun Science-Tech Leasing Co., Ltd. (a company listed on the Hong Kong Stock Exchange, stock code: 1601). In the last three years, Mr. Wu was an independent non-executive director of China Machinery Engineering Corporation, Minth Group Limited and Sinomax Group Limited. Mr. Wu previously served as an independent non-executive director of Beijing Media Corporation Limited (“**Beijing Media**”). Details in relation to the criticism of the current and retired directors of Beijing Media by the Hong Kong Stock Exchange are set out in the announcements of the Hong Kong Stock Exchange and the Company dated 10 February 2022 and 14 February 2022, respectively. Mr. Wu had worked in Deloitte Touche

Tohmatsu, an international accounting firm, for five years. Mr. Wu has served as an independent non-executive Director of the Company since September 2020. Mr. Wu is currently a member of Hong Kong Institute of Certified Public Accountants, a senior fellow member of Hong Kong Securities and Investment Institute, the Association of Chartered Certified Accountants, the Taxation Institute of Hong Kong, and The Hong Kong Chartered Governance Institute.

Mr. Yu Weifeng, aged 52, is an independent non-executive Director of the Company. Mr. Yu is a lawyer with more than 27 years of working experience as a practicing lawyer. Mr. Yu obtained a bachelor's degree in laws from Fudan University in June 1995 and then obtained a master's degree in business administration from China Europe International Business School. From July 1995 to December 1998, Mr. Yu served as a paralegal and lawyer in Shanghai Pu Dong International Law Office (now renamed as Shanghai Pu Dong Law Office). Mr. Yu has served as a partner in Llinks Law Offices since December 1998, and served as a director thereof from January 2014 to June 2020. Mr. Yu currently serves as an independent director of Shenergy Company Limited (a company listed on the Shanghai Stock Exchange, stock code: 600642) and Shanghai M&G Stationery Inc. (a company listed on the Shanghai Stock Exchange, stock code: 603899). Mr. Yu served as an independent director of Deppon Logistics Co., Ltd. and an external director of Jiahua Chemicals Inc. and Shanghai Life Science & Technology Co., Ltd. Mr. Yu has served as the independent non-executive Director of the Company since September 2020. Currently, Mr. Yu is also the chairman of Foreign-related Legal Services Committee of the All China Lawyers Association, president of Shanghai Arbitration Association, a member of Shanghai Arbitration Commission, and an arbitrator of Shanghai Arbitration Commission, Shanghai International Economic and Trade Arbitration Commission (Shanghai International Arbitration Center) and other arbitration institution and a mediator of Shanghai Commercial Mediation Center.

Mr. Shi Shenghao, aged 55, is an independent non-executive Director of the Company. Mr. Shi graduated from Capital Normal University with a bachelor's degree and obtained an EMBA degree from China Europe International Business School. Mr. Shi has more than 30 years of experience in the medical and health industry. He has served as a senior executive and general manager in Greater China for a number of multinational medical companies, and has extensive experience in industry operation and mergers and acquisitions. Mr. Shi is currently the managing partner of Riverhead Capital Investment Management Co., Ltd. Mr. Shi was the managing director of Sinopharm Capital Shanghai Co., Ltd. (國藥資本上海有限公司). He successively served as the marketing and sales director of GE Healthcare, the general manager in Greater China of American Medtronic China Co., Ltd. (美敦力中國有限責任公司), the general manager for diabetes healthcare business in Greater China of Bayer Group and the general manager in Greater China of Dentsply Sirona. Mr. Shi has served as the independent non-executive Director of the Company since June 2023.

As at the date of this announcement, Mr. Yu Qingming has an interest in 100,000 H shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong, same below), and Mr. Liu Yong has an interest in 59,009 H shares of the Company.

Save as disclosed above, none of the above Director candidates for the sixth session of the Board has any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or has any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, none of the above Director candidates for the sixth session of the Board held any other position in the Company or any of its subsidiaries, or any directorship in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matter that needs to be brought to the attention of the Shareholders or any information in relation to the re-election or appointment of the above Director candidates for the sixth session of the Board that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

APPENDIX II BIOGRAPHIES OF THE INDEPENDENT SUPERVISOR AND SHAREHOLDER REPRESENTATIVE SUPERVISOR CANDIDATES FOR THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE

Ms. Guan Xiaohui, aged 52, is the chief Supervisor of the Company. Ms. Guan obtained a bachelor's degree in economics from Jiangxi University of Finance and Economics and obtained a master's degree in accounting for senior accountant from The Chinese University of Hong Kong in December 2007. Ms. Guan is qualified as Chinese Certified Public Account (CPA) and a member of The Association of Chartered Certified Accountants (ACCA). Ms. Guan has joined Fosun Pharma Group since May 2000 and currently serves as an executive director and vice chairman of Fosun Pharma. Ms. Guan worked at Jiangxi Provincial Branch of the Industrial and Commercial Bank of China from July 1992 to May 2000. Ms. Guan served as the non-executive Director of the Company from March 2019 to March 2021 and also once served as a supervisor of Sinopharm Accord. Ms. Guan has served as the Supervisor and the chief Supervisor of the Company since June 2021, and currently also serves as the vice president of Fosun International, a non-executive director of Henlius and a supervisor of Sinopharm Industrial Investment Co., Ltd. Ms. Guan served as a non-executive director of GLAND from October 2020 to August 2022.

Mr. Liu Zhengdong, aged 53, is a Supervisor of the Company. Mr. Liu is a lawyer who has more than 29 years of working experience as a practising lawyer. Mr. Liu obtained a master's degree in laws from East China University of Political Science and Law. He served as an assistant prosecutor in Railway Transportation branch of Shanghai People's Procuratorate from July 1991 to June 1994. From June 1994 to October 1998, Mr. Liu worked at Shanghai Hongqiao Law Firm and has been serving as a lawyer. Mr. Liu worked at Shanghai Junyue Law Firm from October 1998 to February 2022, and served as director and chief partner successively. Mr. Liu has been working in Jun He Law Offices since February 2022 as a partner. Mr. Liu has served as the independent non-executive Director of the Company from September 2014 to September 2020 and has been a Supervisor of the Company since September 2020. Mr. Liu served as president of the Eighth Session of Shanghai Bar Association and was also honored as National Excellent Lawyer and Shanghai Excellent Non-litigation Lawyer. Currently, Mr. Liu serves as a deputy to the 16th People's Congress of Shanghai, the standing director of the National Lawyers Association, the president of Shanghai Bankruptcy Administrators Association (上海市破產管理人協會) and the vice president of Shanghai General Chamber of Commerce. Mr. Liu also serves as an arbitrator of China International Economic and Trade Arbitration Commission (CIETA), Shanghai International Economic and Trade Arbitration Commission (SHIAC) and Shanghai Arbitration Commission (SAC).

Mr. Guo Jinhong, aged 50, is a senior auditor. Mr. Guo received a master's degree in monetary and banking professional economics from Shanxi Institute of Finance and Economics in July 1999. Mr. Guo worked in the Audit Office from July 1999 to March 2019, and served as the general manager of the audit department of Huajin Holdings Group Co., Ltd. (華錦控股集團有限公司) and the general manager of the audit supervisory department of China Railway Construction Capital Holding Co., Ltd. from March 2019 to February 2022. Mr. Guo joined CNPGC in February 2022 and served as the deputy director of the audit department of CNPGC and has served as the director of the audit department of CNPGC since June 2023.

Save as disclosed above, none of the above shareholder representative Supervisor and independent Supervisor candidates for the sixth session of the Supervisory Committee has any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, none of the above shareholder representative Supervisor and independent Supervisor candidates for the sixth session of the Supervisory Committee held any other position in the Company or any of its subsidiaries, or any directorship in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matter that needs to be brought to the attention of the Shareholders or any information in relation to the re-election or appointment of the above independent Supervisor and shareholder representative Supervisor candidates for the sixth session of the Supervisory Committee that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules.